Pro-Pharmaceuticals Provides Year-End Update (Centre Daily Times)
Pro-Pharmaceuticals, Inc. (the Company ) (NYSE Alternext US: PRW) , today provided an update regarding the company s proposed rights offering, pre-New Drug Application (NDA) filing and related meeting with the U.S. Food and Drug Administration (FDA) regarding the company s lead product candidate DAVANAT , NYSE Alternext US stock listing, and cash saving initiatives.

FDA Advisory Committee Unanimously Recommends Approval For New Ophthalmic Product Enabled By InSite's DuraSite ... (Medical News Today)
InSite Vision Incorporated (AMEX:ISV) announced that the U.S. Food and Drug Administration (FDA) Dermatologic and Ophthalmic Drugs Advisory Committee has voted unanimously to recommend approval of Bausch & Lomb's besifloxacin ophthalmic suspension, 0.6%, for the treatment of bacterial conjunctivitis, a product that utilizes InSite Vision's DuraSite patented drug delivery system.